On November 5, 2026, a new publication involving pasireotide appeared in the journal Archives of Endocrinology and Metabolism. The publication is titled "Effectiveness and safety of pharmacological treatments for Cushing's disease: An updated systematic review and meta-analysis."
This publication is listed as a systematic review and meta-analysis covering pharmacological treatments for Cushing's disease. Pasireotide is an approved compound referenced within the scope of this review.
No specific findings, results, or conclusions from the publication have been provided alongside this announcement. This brief reports only that the publication exists, its title, its journal, and its publication date.
Readers interested in further detail should consult the publication directly through the listed source. For additional background on pasireotide, including its approved regulatory status, readers can refer to the compound overview for context.